Cullen/Frost Bankers’s Phibro Animal Health PAHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$49.8K Buy
900
+125
+16% +$5.95K ﹤0.01% 798
2025
Q4
$29K Buy
775
+170
+28% +$6.91K ﹤0.01% 913
2025
Q3
$24.5K Buy
605
+12
+2% +$396 ﹤0.01% 901
2025
Q2
$15.1K Buy
593
+428
+259% +$9.33K ﹤0.01% 968
2025
Q1
$3.53K Buy
165
+25
+18% +$559 ﹤0.01% 1094
2024
Q4
$2.93K Buy
+140
New +$3.24K ﹤0.01% 1090

Other funds holding PAHC

Cullen/Frost Bankers's PAHC Position: Q1 2026 in Review

Cullen/Frost Bankers increased its Phibro Animal Health (PAHC) stake by 16% in Q1 2026, buying an estimated $5.95K and bringing the position to 900 shares worth $49.8K. The position accounts for ﹤0.01% of the portfolio, ranked #798.

Cullen/Frost Bankers first reported a position in PAHC in Q4 2024 and has held it in 6 quarters since. 257 funds tracked by Wall St. Rank hold PAHC as of Q1 2026.

  • Cullen/Frost Bankers held 900 shares of Phibro Animal Health worth $49.8K as of Q1 2026.
  • Cullen/Frost Bankers bought 125 Phibro Animal Health shares in Q1 2026, an estimated $5.95K.
  • Phibro Animal Health made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q1 2026, its #798 holding.
  • Cullen/Frost Bankers first reported a position in Phibro Animal Health in Q4 2024 and has held it in 6 quarters since.
  • 257 funds tracked by Wall St. Rank held Phibro Animal Health as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.